Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Consensus accurately identified the common seven-day gentamicin run-in and within-arm HbA1c changes. Original Methods/Results verify concealed double-blind allocation, drug-naive baseline T2D and synthesized1.2g/day berberine for12weeks. The treatment contrast is approximately0.40 percentage points beyond placebo, not the entire0.99-point fall.391 of409 contributed to the primary analysis. Microbial/metabolite associations do not establish uniquely necessary human mediation. The provider's100% meter across11 items is neither a probability that this mechanism is true nor an examined-original count. Original PMID33024120. Access: full_text_partial.
Consensus correctly separated lipid synergy from glycemic superiority. The original abstract explicitly identifies365 participants from PREMOTE, so the report is counted as an original secondary analysis of the same parent trial rather than a new independent glycemic RCT. Its Bifidobacterium/fadD and postprandial lipid findings do not show that probiotics improve HbA1c beyond berberine, and are not cardiovascular event results. Original PMID34923903. Access: abstract_metadata.
Consensus accurately reports36 randomized new-T2D patients and48 add-on patients. The original abstract distinguishes the active-comparator pilot from the uncontrolled add-on study. Similar changes in the pilot do not demonstrate powered noninferiority, and the whole within-arm HbA1c fall cannot be attributed to the drug without a concurrent comparison. Metformin comparison does not establish modern GLP-1 equivalence. The attempted public XML body retrieval failed; this comparison has abstract/status access only. Original PMID18442638. Access: abstract_metadata.
Consensus correctly names HTD1801 as berberine ursodeoxycholate and reports the high-dose placebo-adjusted0.7-percentage-point HbA1c benefit. Original Methods/Results show113 randomized T2D patients,12weeks and lower-dose0.4-point effect. Weight remained stable. This is a valid distinct-formulation trial, not isolated ordinary-berberine efficacy or evidence of GLP-1-equivalent weight loss. The approximate trial effect does not establish reduced complications. Original PMID40029660. Access: full_text_partial.
Despite the question naming the2026 study, the observed Consensus response did not discuss this337-person ordinary-berberine trial and instead used a different multi-ingredient obesity example. Original Methods/Results verify six-month null effects on visceral fat,liver fat,body composition and glycemic measures, with small lipid/CRP changes. Diabetes was excluded, and an active run-in selected tolerant adherers. This omission matters for broad weight-loss and safety narratives; it does not refute the registered baseline-T2D glycemic effect. Original PMID41543854. Access: full_text_partial.
Consensus accurately reports that Berberis fruit extract improved fasting glucose/lipids but not HbA1c. The original31-person three-month trial confirms a between-arm HbA1c null. The exposure was3g/day multicomponent fruit extract, so it is kept as a formulation boundary rather than a pure-berberine T2D null used to erase placebo-controlled drug results. Original PMID24250489. Access: abstract_metadata.
Consensus reports normalization of prediabetic markers after84days, matching the34-person pilot abstract. Baseline prediabetes, small sample and branded exposure differ from the registered T2D lead. Moving markers below diagnostic thresholds does not establish prevention of future diabetes, durable remission or complication reduction. Original PMID37679692. Access: abstract_metadata.
The question requested KCNH6 and its correction, but the observed provider response did not adjudicate them. Original selected Methods/Results verify acute high-dose global/beta-cell mouse knockout dependence and a single-dose clamp in15 healthy men, not chronic human T2D pathway necessity. Attached correction34716337 was actually read and changes only the author-name spelling Tetsuro Izumi. It adds no primary-study count and does not change numerical results. Original PMID34556670. Access: full_text_partial.
Consensus states that dedicated stack trials are lacking. The original glutathione trial shows increased stores in54 healthy adults after six months, with immune-marker subset results. It tests direct glutathione alone, not berberine/NMN synergy or net clinical benefit. Separate ingredient trials and provider links cannot substitute for an exact combination comparison. Original PMID24791752. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.